Tumor-associated antigens (TAAs) include overexpressed self-antigens (for example, Her2/neu) and tumor virus antigens (for example, HPV-16 E6/E7). Although in cancer patients, TAA-specific CD4 þ and CD8 þ cells are often present, they are not able to control tumor growth. In recent studies, it became apparent that tumor site-located immune evasion mechanisms contribute to this phenomenon and that regulatory T cells have a major role. We tested in Her2/neu þ breast cancer and HPV-16 E6/E7 þ cervical cancer mouse models, whether intratumoral expression of immunostimulatory proteins (ISPs), for example, recombinant antibodies (aCTLA-4, aCD137, aCD3), cyto/chemokines (IL-15, LIGHT, mda-7) and costimulatory ligands (CD80), through adenovirus(Ad)-mediated gene transfer would overcome resistance. In both the breast and cervical cancer model, none of the Ad.ISP vectors displayed a significant therapeutic effect when compared with an Ad vector that lacked a transgene (Ad.zero). However, the combination of Ad.ISP vectors with systemic T regulatory (Treg) depletion, using anti-CD25 mAb (breast cancer model) or low-dose cyclophosphamide (cervical cancer model) resulted in a significant delay of tumor growth in mice treated with Ad.aCTLA4. In the cervical cancer model, we also demonstrated the induction of a systemic antitumor immune response that was able to delay the growth of distant tumors. Ad.aCTLA4-mediated tumor-destructive immune responses involved NKT and CD8 þ T cells. In both models no autoimmune reactions were observed. This study shows that Ad.aCTLA4 in combination with systemic Treg depletion has potentials in the immunotherapy of cancer.
Introduction
Many tumor-associated antigens (TAAs) are nonmutated self-antigens that are overexpressed in tumor cells. A standard example for this class of TAAs is Her2/neu, which is immunogenic and spontaneous; vaccine-induced generation of Her2/neu-specific CD8 þ T cells in breast cancer patients is frequently reported. [1] [2] [3] However, boosting anti-Her2/neu immunity has mostly failed to show clinical benefits. This has been in part attributed to the presence of both central and peripheral tolerance to Her2/neu. [4] [5] [6] [7] Another class of TAAs represents proteins encoded by tumor-associated viruses such as human papillomavirus type 16 (HPV-16), which is a major etiological factor in cervical cancer. 8, 9 Following the demonstration that the E6 and E7 epitopes of HPV16 encode tumor rejection antigens, 10, 11 many therapeutic vaccines, including E6/E7 peptides, fusion proteins and DNA vaccines, have been examined both in animal models and in phase-I or -II clinical trials in humans. However, as observed in breast cancer, intratumoral mechanisms that trigger anergy or tolerance against the HPV-derived TAAs appear to also limit the effect of therapeutic HPV vaccines (for a review, see ref. 12) .
Several cytokines and antibodies have been identified or designed, which have the potential to counteract intratumoral immune tolerance and activate antitumor reactive lymphocytes against immunogenic tumors in vivo. Among cytokines and chemokines that are able to activate tumor-reactive immune cells are interleukin (IL)-15 (ref. 13) , LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with herpes simplex virus glycoprotein-D for herpes simplex virus entry mediator, a receptor expressed by T lymphocytes; TNFSF14) 14 and human melanoma differentiation-associated gene-7 (mda-7)/IL-24 (ref. 15) . Immunostimulatory antibodies include antibodies against CD137 (ref. 16 ; a costimulatory molecule, which is expressed on natural killer (NK) and T-effector cells), antibodies against cytotoxic T-lymphocyte-associated protein-4 (CTLA4, ref. 17 ; a main negative regulator of the immune system, which inhibits the costimulatory signaling for T cells) or antibodies against CD3 in combination with CD28 ligands (which can trigger direct activation of naive T cells). 18 However, the clinical usage of these immunostimulatory proteins (ISPs) is limited because their systemic administration or expression is associated with site effects, specifically with the induction of autoimmune responses. An approach to address this problem involves the tumorlocalized expression of ISP by intratumoral injection or by transductional targeting of gene transfer vectors, thereby increasing the local concentration of ISPs in tumors and minimizing adverse effects associated with their systemic leakage. Another approach to achieve tumor-localized action of ISPs involves anchoring of otherwise secreted ISPs to the membrane of tumor cells. 19 Activation of tumor-destructive immune responses has been shown with membrane-tethered antibodies with specificity for CD3 in combination with CD28 ligation by ectopically expressed B7-2. 20 Likewise, tumorlocated expression of a membrane-tethered antibody against CD137 caused extensive rejection of poorly immunogenic tumors in mice without induction of autoimmunity. 16 In a recent study, we demonstrated that stable expression of an anti-CTLA4 antibody by tumor cells conferred tumor-destructive immune responses, which could be further enhanced by systemic T regulatory (Treg) depletion. 21 To achieve anti-CTLA4 expression, we transduced the tumor cells ex vivo with a lentivirus vector. This approach, however, is difficult to employ clinically. In this study, we therefore tested the antitumor effect of the expression of ISPs in the tumor environment by using adenovirus (Ad) vectors for gene transfer into tumors. Ad vectors have a number of advantages for in vivo gene transfer into tumors, including the ability to efficiently transduce tumor cells after systemic and intratumoral injection and the ability to induce Ad-associated innate and adaptive immune responses that create a proinflammatory environment inside the tumor and facilitate the activation of tumor-antigen-specific T cells, thereby triggering not only anti-virus but also antitumor immunity. Recently, we showed that injection of Ad vectors caused a strong CD4 and CD8 T-cell-mediated immune response against the vectors and vector-transduced tumor cells inside the tumor-draining lymph nodes and in the tumor microenvironment. Importantly, Ad-triggered T-effector cells delayed tumor growth, despite the presence of intratumoral Treg-mediated immune tolerance that suppressed tumor-specific CTLs. 22 Here, we screened a series of ISP genes delivered by Ad vectors for their ability to delay tumor growth in two mouse models that are functionally relevant for breast and cervical cancer. The breast cancer model involves Her2/neu transgenic mice (neu-tg) that harbor nonmutated, nonactivated rat Her2/neu under control of the mouse mammary tumor virus promoter. It has significant biological and pathological similarity to human neuassociated estrogen receptor-negative breast cancer. 23 The mice spontaneously develop breast tumors, which are immunogenic due to the expression of a panel of TAAs (including Her2/neu) similar to human cancer. As most TAAs are nonmutated self-antigens that have triggered both central and peripheral tolerance, neu-tg mice mimic such tolerance to an endogenous tumor antigen. Overall, the tumor antigen repertoire in mouse mammary carcinoma (MMC)-tumor-bearing mice appears to be predictive for human breast cancer antigens. 23 Immune tolerance against the Her2/neu-positive MMC cells is primarily mediated by regulatory T cells. We have recently shown that although implantation of MMC tumors in neu-tg mice triggered Neu-specific T-effector cells inside the sentinel lymph nodes, these cells poorly infiltrated tumors and were functionally inactive in the tumor microenvironment. We also demonstrated that depletion of regulatory T cells enabled activation and clonal expansion of neu-specific CD8 þ T cells in vivo, which subsequently mediated MMC tumor regression. 22 A second tumor model (for cervical cancer) is based on TC-1 cells, a mouse epithelial cancer cell line that expresses HPV-16 E6 and E7 proteins. It is propagated in C57Bl/6 mice and has been frequently used. [24] [25] [26] [27] [28] [29] [30] [31] We have previously shown that TC-1 tumors are infiltrated with E7-specific cells but also contain large numbers of Tregs 21, 32 and that immunotherapy was successful in the TC-1 model, if Tregs were systemically depleted by low-dose cyclophosphamide (CY) injection. 21, 32 Materials and methods 
Cells

Antibodies for immune cell depletion
Monoclonal rat anti-mouse CD25 antibody (PC61.5 hybridoma, ATCC), rat anti-mouse CD4 immunoglobulin-G (IgG; GK1.5, ATTC) and rat anti-mouse CD8 IgG (169.4; ATTC) were produced by culturing hybridoma cell lines in CELLine 1000 culture flasks (BD Biosciences, San Diego, CA) using Dulbecco's modified Eagle's medium supplemented with 10% low IgG fetal bovine serum (Hyclone, Logan, UT), 4 mM L-glutamine, 100 U penicillin ml À1 and 100 mg ml À1 Pen/Strep. Antibodies were purified from hybridoma supernatant using protein-G purification (Amersham Biosciences, Piscataway, NJ) followed by dialysis against phosphate-buffered saline (PBS). NK cell depleting rabbit anti-mouse asalio GM1 IgG were from Cedarlane (Ontario, Canada). Respective IgG isotype controls (isotype1, rat IgG; isotype2, rabbit IgG) were from Jackson ImmunoResearch (West Grove, PA).
Ad vectors
All vectors were based on Ad serotype 5 and had the E1A and E1B genes and the E3 genes deleted. The genomic structures of all vectors are summarized in Supplementary  Figure 1 . Ad.zero is a transgene-devoid vector. Ad.bGal, Ad.IL-15, Ad.LIGHT and Ad.mda7 expressed Escherichia coli b-galactosidase, rat Her/neu, mouse IL-15, mouse LIGHT or human mda7 under the control of the Rous Sarcoma Virus (RSV) promoter. 34 Ad.aCD3 and Ad.aCD137 expressed membrane-bound anti-mouse CD3scFv and anti-mouse CD137scFv under the control of the RSV promotor, respectively. 35, 36 Ad.aCTLA4 was generated by cloning an EcoRV/XhoI fragment of p4F10-g1 (ref. 21) into the EcoRV/SalI sites of pAd.RSV. 37 Ad.CD80 was produced by cloning the coding region for murine CD80 (ref. 38) into pAd.RSV. Recombinant viruses were propagated in 293 cells, banded in CsCl gradients, dialyzed and stored in aliquots as described. 39 To assess contamination of AdE1 À vector preparations with E1 þ replication-competent Ad (RCA), real-time PCR quantification for AdE1 þ genomes was performed. 40 Only virus preparations that contained less than one E1 þ (RCA) viral genome in 1 Â 10 9 genomes were used. Ad-particle (viral particle) concentrations were determined spectrophotometrically by measuring the optical density at 260 nm (OD 260 ). Plaque titering (plaque forming units, p.f.u.) was performed using 293 cells as described elsewhere. 39 The p.f.u./viral particle ratios for all Ad preps was B1:20. Multiplicities of infection in this study were stated as p.f.u. per cell for all assays. Endotoxin contamination was tested with an Endotoxin detection kit (BioWhittaker, Walkerville, MD). All vectors were free of endotoxin.
Validation of transgene expression from Ad vectors MMC and TC-1 cells were transduced with Ad vectors (multiplicity of infection 50) and transgene expression was analyzed 48 h later. Expression of IL-15 and LIGHT proteins was quantified using an IL-15 ELISA Kit (eBioscience, San Diego, CA) and a LIGHT/TNFSF14 ELISA Kit (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. For analysis of aCD3, CD80 and aCD137 expression, Ad-transduced cells were detached 48 h post-transduction using Versene (Gibco, Carlsbad, CA), and expression of membrane-bound proteins was detected by flow cytometry. For Ad.aC-TLA4, serial dilutions of the culture medium were assayed for binding to recombinant CTLA-4 protein coated in microtiter plates by enzyme-linked immunosorbent assay as described earlier. 21 Mda-7 was detected by western blot of cell lysates using rabbit anti-mda7 antibodies (Santa Cruz Biotech., Santa Cruz, CA) as described previously. 41 
Animals
All experiments involving animals were conducted in accordance with the institutional guidelines set forth by the University of Washington. All mice were housed in specific-pathogen-free facilities. C57Bl/6 mice were obtained from Charles River (Wilmington, MA). Neu-tg mice (strain name: FVB/N-Tg(MMTVneu)202Mul) were obtained from the Jackson Laboratory (Bar Harbor, ME). These mice harbor nonmutated, nonactivated rat neu under control of the mouse mammary tumor virus promoter. The neu tg is expressed at low levels in normal mammary epithelium, salivary gland and lung. Until the age of 8 months, B35% of female neu-tg mice spontaneously develop mammary carcinomas that display high Neu expression levels. Immunodeficient NOD.CB17-Prkdc scid /J (CB17/SCID/beige) mice were obtained from the Jackson Laboratory.
Tumor cell transplantation MMC and TC-1 cells were collected using Versene (Gibco) and washed in RPMI-1640 medium (without supplements) before injection. Mice received anesthesia and were injected subcutaneously. Tumors were measured every other day and tumor volume was calculated as the product of length Â width Â width. For survival studies, tumor sizes X500 mm 3 were considered the experimental end point. Animals with skin surface ulcerations were excluded from experiments and killed immediately.
Intratumoral Ad injection
When tumors reached a size of 3-4 mm diameter, mice were randomly assigned to treatment groups. Mice were given anesthesia (Avertin (Sigma, St Louis, MO) intraperitoneally (i.p.)) and then Ad (1 Â 10 9 p.f.u. diluted in 50 ml PBS), or 50 ml PBS was intratumorally injected with constant and low pressure using an insulin syringe (BD Pharmingen).
MMC therapy model
A total of 5 Â 10 5 MMC cells in 100 ml PBS were subcutaneously injected into neu-tg mice. When tumors reached a size of 4 Â 3 mm diameter (usually at day 6 after cell injection), 250 mg of anti-CD25 (or control antibody) in 500 ml PBS was injected i.p. Four days later, Ad vectors were injected intratumorally. Mice then received anti-CD25 or control antibody i.p. once a week.
TC-1 therapy model
A total of 5 Â 10 4 TC-1 cells in 100 ml of PBS cells were subcutaneously injected into C57Bl/6 mice. When tumors Adenovirus vector-based immunotherapy Y Liu et al reaches a diameter of 2 Â 3 mm (usually at day 5 after cell injection), mice received an intraperitoneal injection of CY (2 mg per mouse in 500 ml PBS) as described previously. 21 Four days later, Ad vectors were injected intratumorally.
TC-1 vaccination model
A total of 1 Â 10 4 TC-1 cells were injected subcutaneously into the right inguinal flank of C57Bl6 mice. When tumors reached a diameter of B2 mm, mice received an intraperitoneal injection of low-dose CY. Four days later, a total of 1 Â 10 6 Ad-transduced TC-1 cells were transplanted into the left inguinal flank. TC-1 cells were infected ex vivo with Ad vectors at a multiplicity of infection of 100 p.f.u. per cell. Twenty-four hours after Ad infection, cells were trypsinized, washed and used for transplantation.
þ T cells and NK cells were depleted using intraperitoneal injection of the following antibodies diluted in 500 ml PBS: 200 mg rat anti-mouse CD4 IgG (GK1.5, ATTC), 200 mg rat anti-mouse CD8 IgG (169.4; ATTC) or 20 ml rabbit anti-mouse asalio GM1 IgG (Cedarlane). A quantity of 200 mg of the respective IgG isotype control (Jackson ImmunoResearch) was used in control animals (isotype1, rat IgG; isotype2, rabbit IgG). For some experiments, injection of each antibody was repeated every 3 days to maintain the depletion.
Flow cytometry
Flow cytometry was performed using a BD FACSCalibur (BD Biosciences). Samples were pretreated with Fc-block (anti-CD16/CD32, BD Biosciences) for 15 min, stained for 30 min on ice in washing buffer (PBS-1% fetal bovine serum) and washed three times with washing buffer. Fluorescein isothiocyanate (FITC)-or phycoerythrinconjugated isotype controls were included in all experiments. Anti-E-cadherin-phycoerythrin antibody (clone 114420, R&D Systems) was used to detect MMC cells. For flow cytometry analysis of immune cells, the following monoclonal antibodies were used: anti-FoxP3-phycoerythrin (clone FHK16s; cells were permeabilized according to the manufacturer's instruction; eBioscience), anti-CD4-FITC (clone RM4-5), anti-CD8-FITC (clone 53-6.7), anti-NK1.1-phycoerythrin (clone PK136). For CD25 flow cytomety, another monoclonal antibody isotype was used than for Treg depletion.
Immunofluorescence studies Tumor slides were fixed with acetone/methanol (10 min) and washed twice with PBS. Slides were blocked for 20 min at room temperature using PBS-5% blotting grade milk (Bio-Rad, Hercules, CA) followed by incubation with primary antibodies in PBS for 1 h at room temperature. Then slides were washed twice with PBS and incubated with secondary antibodies for 1 h at room temperature followed by washing with PBS three times. Slides were washed twice with PBS, mounted with Mounting Medium for Fluorescence (Vector Laboratories, Burlingame, CA) and then analyzed using a fluorescence microscope. Laminin was detected using anti-laminin polyclonal (primary) antibody (1:200; #Z0097; Dako, Carpinteria, CA) and goat anti-rabbit IgG Alexa Fluor568 (secondary) antibody (1:200; Molecular Probes, Carlsbad, CA); the following cell surface markers were used: FITC-labeled anti-E-cadherin antibody (1:100; clone 36/E-Cadherin, BD Biosciences) or FITC-labeled anti-CD4, anti-FoxP3, and anti-CD8 antibodies (see 'Flow cytometry'). Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (Sigma).
Immunohistochemistry of mouse tissue and organs
For histological assessment of autoimmune disease, mouse tissues and organs (heart, lung, brain, stomach, mesenterium, liver, kidney, muscle and skin) were fixed in 10% formalin and processed for hematoxylin and eosin staining. All samples were examined by two experienced pathologists for typical inflammation signs in a blinded manner. Immunohistochemistry for IgG on kidney sections was performed as described for tumor sections using a polyclonal, horseradish peroxidase-labeled, antimouse IgG antibody (eBiosciences).
Statistical analysis
Statistical significance of in vivo data was analyzed by Kaplan-Meier survival curves and log-rank test (GraphPad Prism Version 4, La Jolla, CA). Statistical significance of in vitro data was calculated by two-sided Student's t-test (Microsoft Excel). P-values 40.05 were considered not statistically significant.
Results
Studies in Her2-transgenic mice with MMC tumors
We tested seven E1/E3 deleted, Ad5-based Ad.ISP vectors expressing the following ISPs: anti-CD3, mouse CD80, anti-CD137, anti-CTLA4, mouse IL-15, mouse LIGHT or mda7. Transgenes were under the control of the RSV promoter (Supplementary Figure 1) . This promoter provides efficient transgene expression in MMC and TC-1 cells in vitro and in vivo. 21, 32 A control vector (Ad.zero) contained the RSV promoter without any transgene. Expression of ISPs after Ad infection of MMC and TC-1 cells was validated as described earlier 22 and in the Materials and methods section.
MMC tumors were established by subcutaneous injection of tumor cells into neu-tg mice. MMC tumors grew aggressively and reached a size of 500 mm 3 within 14 days after cell implantation. Tumors contained nests of epithelial tumor cells with intercellular tight and adherens junctions (Figure 1a , E-cadherin staining). Tumor nests were surrounded by extracellular matrix (Figure 1b , laminin staining). Tumors were infiltrated with CD4, CD8 and Tregs (Figures 1c and d) . Overall, this histology is very similar to that observed in breast cancer patient biopsies. 21 Intratumoral injection of Ad.bGal resulted in efficient transgene expression predominantly localized around the needle track (Figure 1e ). Flow cytometry analyses of tumor cell suspensions showed b-galactosidase expression in 18( ± 7)% of tumor cells (data not shown).
To assess tumor toxicity of Ad.ISP vectors by mechanisms other than immune-mediated tumor destruction, we studied the effect of Ad.ISP injection in MMC tumors established in immunodeficient CB17-SCID/beige mice, which are impaired for T-cell and NK-cell function. These tumors were similar to those in neu-tg mice with regard to epithelial/nodular phenotype and extracellular matrix. In the MMC/CB17-SCID/beige model, we did not find significant differences between PBS, Ad.zero and Ad.ISPinjected animals, indicating that the expression of the transgene product or the Ad injection procedure did not exert antitumor effects. Notably, T-cell stimulation through CD3 ligands requires costimulatory signals, such as activation of CD28. We therefore employed AdaCD3 together with Ad.CD80.
In a therapy study in neu-tg mice, 2 Â 10 9 p.f.u. of Ad.ISP vectors were injected into MMC tumors (average size B50 mm 3 ). All vectors significantly increased the median survival in neu-tg mice for at least 5 days compared with PBS-injected mice (Po0.05; Figure 2a , Supplementary Figure 2) . However, there was no significant difference between the control vector, Ad.zero and the Ad.ISP vectors. This indicated that vectortriggered immune responses have a significant antitumor effect in this model, as we did not observe a tumor-growth delay in immunodeficient mice. However, expression of ISP did not have an adjuvant effect on this antitumor immune response. As Treg cells have been shown to mediate immune tolerance toward tumor antigens in this model, 22 we decided to test Ad.ISP vectors in combination with systemic depletion or inactivation of Tregs. An approach that we and others successfully applied in various tumor models (TC-1, B16 or PC61) utilizes intraperitoneal injections of low-dose (100 mg kg À1 ) CY. 21, 42, 43 To evaluate the effect of low-dose CY on MMC tumors, we injected MMC-tumor-bearing CB17-SCID/beige mice with 100 mg kg À1 CY and measured tumor growth (Figure 2b, Supplementary Figure 3A) . CY resulted in a marked inhibition of tumor growth, indicating a direct toxic effect on MMC cells. Decreasing the CY dose to 50 mg kg À1 affected MMC tumor growth less, but did not result in efficient depletion of CD4/CD25 cells. 21 In contrast, an approach for Treg depletion that involved intraperitoneal injection of anti-CD25 antibodies (250 mg per mouse i.p.), which did not delay MMC tumor growth in CB17/SCID-beige mice (Figure 2c,  Supplementary Figure 3B) , significantly reduced Tregs in neu-tg mice, as CD4, CD25 and FoxP3 flow cytometry studies with splenocytes showed (Figure 2d ). To test the therapeutic effect of the combined anti-CD25/Ad.ISP approach, MMC tumors with an average volume of 50 mm 3 were intratumorally injected with Ad.ISP or Ad.zero (1 Â 10 9 p.f.u.) 4 days after the mice had been injected with anti-CD25 or isotype control Ig. Pre-injection of anti-CD25 did not significantly increase median survival of Ad.zero (Figure 2e ), Ad.IL-15, Ad.LIGHT, Ad.aCD3/Ad.CD80 and Ad.aCD137-injected mice (not shown). However, the combination of anti-CD25 and Ad.aCTLA4 had a significant therapeutic effect reflected in prolonged survival compared with Co-Ig/Ad.aCTLA4 and anti-CD25/Ad.zero groups (Figure 2f) . None of the anti-CD25/Ad.aCTLA4-treated mice displayed signs of autoimmune responses detectable as changes in fur color or organ inflammation (assessed on tissue sections).
Studies in C57Bl/6 mice with TC-1 tumors Because the outcome of immunotherapy approaches greatly depends on the phenotype of the tumor and mouse strain, we tested our Ad.ISP vectors in a second As seen in the MMC/neu-tg model, intratumoral injection of Ad.ISP vectors into TC-1 tumors as a single agent did not result in significant delay of tumor growth (Figure 4a) . While in the MMC model, Ad injection (including Ad.zero injection) delayed tumor growth compared with PBS-injected mice, this effect was not observed in the TC-1 model, which might be due to less immunogenicity of Ad in this mouse strain.
Previous studies showed that low-dose CY injection in the TC-1 model resulted in efficient Treg depletion without direct killing of TC-1 tumor cells. 21 We therefore tested our Ad.ISP vectors in combination with Treg depletion by low-dose CY. This approach resulted in significant prolongation of survival when mice received intratumoral Ad.aCTLA4 and Ad.aCD3/Ad.CD80 in combination with systemic Treg depletion (Figure 3b ). Intratumoral injection of Ad.zero and the other Ad.ISP vectors (Ad.IL-15, Ad.aCD137, Ad.LIGHT and Ad.mda7) combination with CY did not result in a significant increase of survival compared with PBSinjected mice that received CY (Supplementary Figure  4) . Separate injection of Ad.aCD3 and Ad.CD80 plus CY also failed to exert therapeutic effects.
Next we employed a vaccination regimen to study whether this approach mediates the induction of a systemic antitumor response that is able to control growth of tumors at distant sites that were not transduced by Ad vectors.
To avoid Ad dissemination in vivo and minimize growth of the 'vaccination' tumor, we infected TC-1 cells ex vivo This study also demonstrates that both Ad.ISP vectors trigger TC-1-specific immune responses, excluding a major role of anti-Ad responses in tumor destruction in the therapy scheme shown in Figure 4c .
We used the TC-1 model to study which arm of the immune system conferred Ad.aCTLA4-mediated antitumor immune responses. Three weeks after TC-1 cell implantation, primary (pre-established) tumors, tumordraining lymph nodes and spleens from treated mice were analyzed by flow cytometry for CD4, CD8, FoxP3 (Tregs) and CD3/NK1.1 (NKT cells; Figure 5a ). At all three sites, we found more CD3 þ /NK1.1 þ NKT cells in mice that were vaccinated with Ad.aCTLA4-infected TC-1 cells compared with mice that received Ad.zero-transduced TC-1 cells. Furthermore, in tumors the number of CD8 þ T cells was significantly increased in the Ad.aCTLA4 group (2.4-fold). Because CY was given at day 5 after TC-1 cell transplantation, it is not expected that, at the time of T-cell analysis (day 22), the Treg cell numbers are still affected by CY.
To corroborate our findings, we depleted CD4 þ , CD8
þ T cells and NK cells over the entire period of Figure 5B) .
In both the MMC and TC-1 tumor models, none of the anti-CD25/Ad.aCTLA4-treated mice displayed signs of autoimmune responses detectable as changes in fur color. To further assess potential autoimmune reactions, organs of TC-1/Ad.aCTLA4 vaccinated, CY-treated mice were collected, paraffin embedded, and sectioned for hematoxylin and eosin staining. No evidence of inflammatory processes (for example, mononuclear infiltrations) was detectable in these mice ( Figure 6 ). Furthermore, immunohistochemistry staining for IgG complexes on kidney sections did not reveal abnormalities.
Discussion
We tested a series of Ad.ISP vectors in two aggressively growing syngeneic tumor models. Similar to what is seen in humans, in both models intratumoral Tregs were involved in the protection of tumors against immunemediated destruction. In our studies, we found that these mechanisms also blocked potential therapeutic effects of Ad.ISP vectors. Only when Tregs were depleted or functionally inactivated (either by low-dose CY or anti-CD25 injection), Ad.aCTLA4 and Ad.aCD3 þ Ad.CD80 triggered significant, immune-mediated delay of tumor growth. The first vector expressed an antibody against CTLA4. CTLA4 is a main negative regulator of the CD80. It is thought that expression of both aCD3 and CD80 reduces the dependency of T-cell activation on major histocompatibility complex expression, which is often absent or low on tumor cells. Previous studies in the B16 melanoma model have shown that Ad-mediated overexpression of aCD3 and the CD28 ligand CD86 in combination with Treg depletion induced potent antitumor immune responses. 42 A problem associated with systemic application of immunostimulatory antibodies in preclinical and clinical studies are toxic side effects. In humans who received anti-CTLA4 antibodies, these included colitis and skin rash as well as a variety of autoimmune and inflammatory processes against multiple organs. 46, 47 There is a prevalent thought that toxicity and response are correlated after therapy with anti-CTLA4 blocking monoclonal antibodies. Our studies with tumor-localized expression of immunostimulatory antibodies, however, indicate that this is not necessarily correct as we did not observed signs of autoimmunity in our models. In this study, preferentially tumor-localized transgene expression is achieved through local application of Ad vectors into subcutaneous tumors. Our studies in the TC-1 model indicate that the Ad.aCTLA4-based approach has the potential to induce a systemic immune response that can also control distant tumor sites that were not injected with the Ad.ISP vector.
While Ad vectors have clear advantages for tumor cell immunotherapy (high efficiency in vivo tumor transduction, induction of a proinflammatory milieu inside the tumor and so on), they also trigger strong anti-Ad immune responses, which potentially can compete with immune responses against the relatively low immunogenic TAAs. In a recent study, we found, however, that anti-Ad T-cell immune responses after intratumoral Ad injection can cause collateral damage and kill tumor cells and that Ad-mediated antitumor efficacy is further enhanced by pre-existing anti-Ad immunity. 22 Overall, our study provides a basis for Ad-based immunotherapy, particularly for the combination of Ad.aCTLA4 and systemic Treg depletion. 
